Lithium Reduces Tau Phosphorylation but Not Aβ or Working Memory Deficits in a Transgenic Model with Both Plaques and Tangles
- 31 May 2007
- journal article
- Published by Elsevier BV in The American Journal of Pathology
- Vol. 170 (5), 1669-1675
- https://doi.org/10.2353/ajpath.2007.061178
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- Chronic lithium treatment decreases tau lesions by promoting ubiquitination in a mouse model of tauopathiesActa Neuropathologica, 2005
- Lipopolysaccharide-Induced Inflammation Exacerbates Tau Pathology by a Cyclin-Dependent Kinase 5-Mediated Pathway in a Transgenic Model of Alzheimer's DiseaseJournal of Neuroscience, 2005
- Lithium Chloride Increases the Production of Amyloid-β Peptide Independently from Its Inhibition of Glycogen Synthase Kinase 3Journal of Biological Chemistry, 2005
- Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degenerationin vivoProceedings of the National Academy of Sciences, 2005
- Chronic nicotine administration exacerbates tau pathology in a transgenic model of Alzheimer's diseaseProceedings of the National Academy of Sciences, 2005
- MARK/PAR1 kinase is a regulator of microtubule-dependent transport in axonsThe Journal of cell biology, 2004
- Aβ Immunotherapy Leads to Clearance of Early, but Not Late, Hyperphosphorylated Tau Aggregates via the ProteasomeNeuron, 2004
- Bipolar DisorderNew England Journal of Medicine, 2004
- Lithium activates the serine/threonine kinase Akt-1 and suppresses glutamate-induced inhibition of Akt-1 activity in neuronsProceedings of the National Academy of Sciences, 1999
- Glycogen synthase kinase-3β phosphorylates tau protein at multiple sites in intact cellsNeuroscience Letters, 1995